BRIEF-GSK, Theravance submit sNDA to U.S. FDA for Breo Ellipta

June 30 Mon Jun 30, 2014 8:08am EDT

June 30 (Reuters) - Glaxosmithkline Plc :

* GSK and Theravance announce submission to US regulatory authorities for Fluticasone Furoate/Vilanterol in asthma

* Today's filing is based upon data generated from comprehensive clinical development programme for FF/VI in asthma

* sNDA is seeking approval for two dose regimens, 100/25mcg and 200/25mcg, administered once daily using Ellipta dry powder inhaler Source text for Eikon: Further company coverage:

A couple walks along the rough surf during sunset at Oahu's North Shore, December 26, 2013. REUTERS/Kevin Lamarque

Find your dream retirement town

Florida? Hawaii? Reuters has teamed up with Zillow to give you the power to customize a list of your best places to retire.  Video | Full Article